Immutep : Corporate Presentation

Unlocking the power of the immune system to fight cancer and autoimmune disease.

I Corporate Presentation - June 2023 (ASX: IMM, NASDAQ: IMMP)

Forward-Looking Statements

The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This presentation is authorised for release by the CEO of Immutep Limited.

2

Immutep Highlights

Novel science and

Compelling

Validation through

Global presence;

Substantial market

advanced pipeline

clinical data

partnerships

strong balance sheet

opportunity

Pioneering LAG-3

First-in-class eftilagimod

Multiple partnerships

Global presence and

Efti has safely improved

immunotherapy in cancer

alpha (efti) has generated

and collaborations with

strong IP across diversified

clinical outcomes for cancer

& autoimmune diseases.

compelling clinical efficacy

large pharma.

LAG-3 portfolio.

patients with anti-PD-(L)1

Three clinical assets and

with favourable safety

Well-funded.

therapies and chemo

two earlier stage programs.

across several cancers.*

creating large opportunity.

*(1) Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II) - SITC 2022 Oral Presentation; (2) Biomarker and multivariate analyses results from AIPAC: A phase IIb study

3 comparing eftilagimod alpha (a soluble LAG-3 protein) to placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast carcinoma. ESMO - May 2022; (3) Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC) SITC 2021.

Deep Pipeline

ONCOLOGY

	Program	Indication
		1L Head & Neck Squamous Cell Carcinoma (HNSCC)
	Eftilagimod Alpha	1L Non-Small Cell Lung Cancer (NSCLC),
	2L HNSCC, PD-X Refractory 2L NSCLC
	Soluble LAG-3 Protein
	Urothelial Cancer
		1L NSCLC
		Soft Tissue Sarcoma
		HR+/HER2- Metastatic Breast Cancer & TNBC
		Metastatic Breast Cancer & Solid Tumors
	Anti-LAG-3	Undisclosed
	Small Molecule
		Solid Tumors & Blood Cancer
	LAG525	Triple Negative Breast Cancer
	Anti-LAG-3	Melanoma
	Antibody	Solid Tumors
		Triple Negative Breast Cancer

Preclinical

Phase I

TACTI-003 | Efti+Pembrolizumab a

TACTI-002 | Efti+Pembrolizumab a

INSIGHT-005 | Efti+Avelumab §, b

INSIGHT-003 | Efti+Pembro+Chemo §

EFTISARC-NEO | Efti+Pembro+Radiotherapy §

AIPAC-003 | Efti+Paclitaxel

Efti+Paclitaxel and Efti+Pembrolizumab #

Phase II

Late Stage*

Collaborations	Commercial Rights

Global Rights

ex-China

Efti China Rights

Global Rights

Global Rights

AUTOIMMUNE DISEASE

GSK'781	Ulcerative Colitis
Depleting LAG-3	Psoriasis
Antibody	Healthy Subjects
IMP761	Undisclosed
Agonist LAG-3
Antibody

Global Rights

Global Rights

Information in pipeline chart current as of May 2023;AIPAC-003 Phase II/III trial expected to begin Q1'2023. For EOC's China rights, Immutep may receive undisclosed milestones plus royalties; LAG525 - ClinicalTrials.gov (for Novartis' global rights, Immutep may receive milestones plus royalties); GSK2831781 -

4 ClinicalTrials.gov (for GSK's global rights, Immutep may receive milestones plus royalties), Phase II in Ulcerative Colitis discontinued. * Late stage refers to active Phase IIb clinical trials or more clinically advanced clinical trials; # Conducted by EOC in China. Immutep has no control over either the trials. § Investigator Initiated Trials controlled by lead investigator & therefore Immutep has no control over this clinical trial; a In combination with KEYTRUDA®; b In combination with BAVENCIO®.

Immuno-Oncology (IO) Landscape

LAG-3 is one of three Immune Checkpoints with Regulatory Approvals

Timeline of Immune Checkpoint Discovery*

Evolution of Immuno-Oncology Therapies**

OPDIVO &

KEYTRUDA

OPDIVO &

Yervoy

& chemo

Relatlimab

(anti-LAG-3)

Yervoy

OPDIVO

(anti-CTLA-4)

(anti-PD-1)

KEYTRUDA

(anti-PD-1)

2011

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

2022

The immune system's role in fighting cancer has led to regulatory approval of

immuno-oncology therapies targeting the immune checkpoints CTLA-4,PD-1, and LAG-3

LAG-3 is unique in that its (1) inhibition on T cell receptor signalling and (2) activation of dendritic cells both engage the immune system to fight cancer

5 *Checkpoint Inhibitors: Applications for Autoimmunity, Springer, September 2017Current Allergy and Asthma Reports 17(10) DOI:10.1007/s11882-017-0740-z. ** Yervoy (ipilimumab), OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), Opdualag (nivolumab + relatlimab)